CMS gives InVision dedicated Medicare payment for cardiac amyloidosis AI

CMS finalized a New Technology Add-on Payment for InVision’s AI software that detects cardiac amyloidosis from echocardiograms, creating a Medicare reimbursement path for inpatient use starting Oct. 1, 2026. The decision gives the company payment coverage across inpatient, outpatient and physician-office settings for a disease that is often missed until late.

Why it matters: - CMS approval gives InVision a dedicated Medicare payment path for Precision Cardiac Amyloid in inpatient care. - The add-on payment can reduce a reimbursement barrier that may slow adoption of AI tools in hospital echo labs. - Cardiac amyloidosis is often underdiagnosed and diagnosed late, when outcomes worsen. - The coverage now extends across inpatient, hospital outpatient and physician-office settings.

What happened: - CMS finalized a New Technology Add-on Payment for InVision Precision Cardiac Amyloid in the FY 2027 Inpatient Prospective Payment System final rule. - The inpatient payment takes effect for discharges on or after Oct. 1, 2026. - Eligible inpatient cases can receive up to $2,275.00 per stay on top of the standard MS-DRG payment. - InVision said Category III CPT code 0932T has been active for hospital outpatient and physician-office studies since Jan. 1, 2025. - The company said the Medicare payment pathway is now defined across both inpatient and outpatient settings.

The details: - Precision Cardiac Amyloid is FDA-cleared AI software that analyzes routine transthoracic echocardiography. - The software looks at apical four-chamber and parasternal long-axis views to flag patients at high risk for cardiac amyloidosis. - The underlying algorithm was published in JAMA Cardiology in 2022. - In a head-to-head evaluation published in JACC Advances in 2025, the product delivered twice the positive predictive value of a comparator algorithm, which translates into fewer false positives and fewer unnecessary confirmatory workups. - InVision said the technology is the first AI echocardiography product to receive a dedicated Medicare add-on payment for cardiac amyloidosis. - InVision said it is also the only echocardiography technology approved for an NTAP in FY 2027 under the alternative pathway. - The technology received FDA 510(k) clearance on May 21, 2025. - The product had previously earned FDA Breakthrough Device Designation. - The indication covers adult patients age 65 and older undergoing cardiovascular assessment with echocardiography when used by an interpreting physician. - Hospitals seeking the inpatient add-on payment will use ICD-10-PCS code XEZZXLC, which stands for "Computer-aided detection and notification for imaging abnormalities in echocardiography, new technology group 12." - The ICD-10-PCS code is effective for dates of service on or after Oct. 1, 2026. - Health systems can find NTAP and CPT coding guidance at reimbursement guidance.

Between the lines: - The Medicare decision turns an AI detection tool into something that can be billed in routine care, not just tested in specialized settings. - For InVision, payment coverage may matter as much as regulatory clearance because hospitals often weigh reimbursement before adopting new technology. - The company is positioning echocardiography as an early screening point for a disease that can hide inside common heart-failure evaluations. - The claims about improved clinical access and broader adoption are forward-looking and depend on hospital implementation.

What's next: - Hospitals can begin preparing for inpatient use tied to XEZZXLC before the Oct. 1, 2026 effective date. - Health systems can use the existing outpatient CPT code 0932T for studies performed in hospital outpatient and physician-office settings. - InVision is likely to push implementation support as providers evaluate whether to add the software to echo workflows.

The bottom line: - CMS has now created a full Medicare payment path for InVision’s cardiac amyloidosis AI, removing a key barrier to broader use in routine echocardiography.